These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22965699)

  • 1. Clinical study of western medicine combined with Chinese medicine based on syndrome differentiation in the patients with polarized hypertension.
    Chen SL; Liu XY; Xu WM; Mei WY; Chen XL
    Chin J Integr Med; 2012 Oct; 18(10):746-51. PubMed ID: 22965699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate.
    Kereiakes DJ; Neutel JM; Punzi HA; Xu J; Lipka LJ; Dubiel R
    Am J Cardiovasc Drugs; 2007; 7(5):361-72. PubMed ID: 17953475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
    Lewin AJ; Weir MR
    Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
    Neutel JM; Germino FW; Smith D
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):84-9. PubMed ID: 16470487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
    Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
    Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.
    Schrader J; Bramlage P; Lüders S; Thoenes M; Schirmer A; Paar DW
    Clin Drug Investig; 2007; 27(11):783-96. PubMed ID: 17914897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension.
    Lacourcière Y
    Clin Ther; 2000 Oct; 22(10):1213-24. PubMed ID: 11110232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients.
    Hosaka M; Inoue R; Satoh M; Watabe D; Hanazawa T; Ohkubo T; Asayama K; Obara T; Imai Y;
    Clin Exp Hypertens; 2018; 40(5):468-475. PubMed ID: 29172732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of two treatment combinations of hypertension in very elderly patients.
    Fogari R; Zoppi A; Mugellini A; Corradi L; Lazzari P; Preti P; Derosa G
    Arch Gerontol Geriatr; 2009; 48(3):401-5. PubMed ID: 18457886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care.
    Bramlage P; Pittrow D; Kirch W
    Curr Med Res Opin; 2004 Oct; 20(10):1625-31. PubMed ID: 15462695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
    Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
    Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension.
    Coca A; Calvo C; Sobrino J; Gómez E; López-Paz JE; Sierra C; Bragulat E; de la Sierra A
    Clin Ther; 2003 Nov; 25(11):2849-64. PubMed ID: 14693309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy.
    Cushman WC; Neutel JM; Saunders E; Bakris GL; Ferdinand KC; Ofili EO; Sowers JR; Madder R; Weber MA
    Am J Geriatr Cardiol; 2008; 17(1):27-36. PubMed ID: 18174757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irbesartan reduces QT dispersion in hypertensive individuals.
    Lim PO; Nys M; Naas AA; Struthers AD; Osbakken M; MacDonald TM
    Hypertension; 1999 Feb; 33(2):713-8. PubMed ID: 10024334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors.
    Franklin SS; Neutel JM
    J Clin Hypertens (Greenwich); 2010 Jul; 12(7):487-94. PubMed ID: 20629810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.
    Chrysant SG; Neutel JM; Ferdinand KC;
    J Natl Med Assoc; 2009 Apr; 101(4):300-7. PubMed ID: 19397219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison.
    Lee HY; Kang HJ; Koo BK; Oh BH; Heung-Sun K; Kim KS; Seo HS; Ro YM; Kang JH; Woong CJ; Joo SJ; Kim MH; Joon-Han S; Yoon J; Park SH; Jin-Ok J; Ju AK; Chong-Yun R; Yeon KJ; Park KM; Lim DK; Park SY;
    Clin Ther; 2005 Jun; 27(6):728-39. PubMed ID: 16117979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial.
    Ofili EO; Cable G; Neutel JM; Saunders E
    J Womens Health (Larchmt); 2008; 17(6):931-8. PubMed ID: 18681815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan.
    Mancia G; Korlipara K; van Rossum P; Villa G; Silvert B
    Blood Press Monit; 2002 Apr; 7(2):135-42. PubMed ID: 12048432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.